First quarter in brief 1 January – 31 March 2019 Net sales for the period (January to March) amounted to SEK 0.0 million (SEK 0.0 million) R&D costs for the period amounted to SEK 10,2 million (SEK 11,8 million)....
Read MorePERIOD JAN – SEPTEMBER 2018, AND THIRD QUARTER IN BRIEF • Net sales for the period (January to September) amounted to SEK 0.1 million (SEK 0.1 million) of which the third quarter amounted to SEK 0.1 million (SEK 0.0 million). • R&D...
Read MoreToday, Friday, April 27, 2018 is the last day of trading in Kancera’s share, including the right to participate in the rights issue. Otherwise, the following time plan applies (dates refer to 2018): Friday April 27th: Last day for trading...
Read MorePERIOD 1 JAN – 31 DEC 2017 IN BRIEF • Net turnover for the period amounted to SEK 0.1 million (0.3 million). For the fourth quarter, turnover amounted to 0.0 MEK (0.1 M). • R & D expenses for the period amounted to...
Read MoreAccording to the agreement with Acturum Real Estate AB, the second partial payment for the Fractalkine project is due when the drug candidate KAND567 has been given to a certain number of subjects in the ongoing Phase Ia study.Therefore,...
Read MorePERIOD 1 JAN – 30 SEPT 2017 IN BRIEF • R&D expenses for the period amounted to SEK 39.8 million (13.3 million ), of which the third quarter amounted to SEK 14.7 million (4.6 million ) • Operating profit for the period amounted to...
Read MoreTHE PERIOD JANUARY – DECEMBER 2016 IN BRIEF R&D expenses for the period amounted to SEK 19,1M (SEK 20,4M) of which the fourth quarter constituted SEK 5.8M (SEK 8,3M). Operating income for the period amounted to SEK -22,3M (SEK -19.7M)...
Read MoreThe period January to September 2016 in brief R&D expenses for the period amounted to SEK 13.3m (SEK 12.1m) of which the third quarter constituted SEK 4.6m (SEK 3.2m). Operating income for the period amounted to SEK -15.8m (SEK...
Read More